Golimumab Injection Articles
Janssen files BLA for IV form of Simponi for moderate-to-severe RA
20 September 2012
US gastroenterologists' attitudes to prescribing for Crohn's disease and ulcerative colitis
9 September 2012
More news at EULAR from Novartis, J&S and B-MS
7 June 2012
Janssen Biotech gets FDA delay for new Simponi indication
12 September 2011
Merck & Co and Johnson & Johnson settle long-running battle over Remicade and Simponi marketing; J&J eyeing Swiss acquisition
18 April 2011
UK’s NICE backs Merck & Co’s Simponi and Amgen’s Nplate
18 March 2011
Abbott prevails as US Court of Appeals overturns $1.8 billion patent verdict for J&J unit
24 February 2011
Abbott/Eisai's Humira emerges as market leader in psoriatic arthritis, garnering sales of over $500 million in 2009
5 November 2010
Rheumatoid arthritis patient share of Actemra projected to exceed that of Cimzia and Simponi among US Medicare population
4 November 2010
UK NICE Appraisal Consultation on Merck & Co’s Simponi for rheumatoid arthritis initially negative
22 October 2010
UK’s NICE does about turn on Alzheimer’s drugs but unable to recommend Merck & Co/J&J’s psoriatic arthritis drug Simponi
7 October 2010
FDA appro for J&J arthritis drug Simponi
28 April 2009
RA golimumab patients see DAS28 remissions
23 June 2008
Showing 1-22 of 22 articles
- 1
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
